Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 17/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 17/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.47 |
| ▸ | TSHR | P16473 | 13/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452114 | 1.00 | MAPT (0.47) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL30451498 | 0.86 | MAPT (0.58) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL29015444 | 0.86 | MAPT (0.49) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL30451795 | 0.86 | CYP1A2 (0.45) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL24252778 | 0.86 | CYP1A2 (0.45) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL24252396 | 0.84 | CYP1A2 (0.44) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL30451975 | 0.84 | CYP1A2 (0.44) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL24252754 | 0.84 | MAPT (0.47) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL24252972 | 0.83 | MAPT (0.56) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL30451901 | 0.83 | MAPT (0.56) | MAPTCYP1A2CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MAPT 1152/4885CYP1A2 2977/4885CYP3A4 2694/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MAPT 1152/4885CYP1A2 2977/4885CYP3A4 2694/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | MAPT 1152/4885CYP1A2 2977/4885CYP3A4 2694/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | MAPT 4803/4885CYP1A2 4150/4885CYP3A4 4043/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | MAPT 4737/4885CYP1A2 3838/4885CYP3A4 3719/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MAPT 1152/4885CYP1A2 2977/4885CYP3A4 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.